Clinical Improvement After Duodenojejunal Bypass for Nonobese Type 2 Diabetes Despite Minimal Improvement in Glycemic Homeostasis
- 311 Downloads
Glycemic control of type 2 diabetes mellitus (T2DM) remains a dilemma to physicians. Although gastric bypass surgery undertaken for morbid obesity has been shown to resolve this disease well, data on the effectiveness of duodenojejunal bypass in improving or resolving T2DM and the metabolic syndrome (MS), especially in nonobese patients are scarce. This study was intended to evaluate the clinical effects of laparoscopic duodenojejunal bypass (LDJB) in patients with T2DM and a body mass index of <35 kg/m2.
We conducted a 12-month prospective study on the changes in glucose homeostasis and the MS in seven T2DM subjects undergoing LDJB with similar DM duration, type of DM treatment, and glycemic control. Laboratory values including glycosylated hemoglobin A (HbA1c), fasting blood glucose, cholesterol, triglyceride, and C-peptide were followed throughout the 12 months. Serum levels of gastric inhibitory peptide and ghrelin were followed for 1 month. Serum levels of gastrin and glucagon-like peptide were followed for 3 months.
At 12 months after surgery, all subjects consistently felt relief from fatigue, pain and/or numbness in the extremities, polyuria, and polydypsia. Clinical resolution was obtained for one patient, and the preoperative diabetic medication requirements decreased for most of the other patients. The subjects demonstrated an overall improved HbA1c (from 9.4% to 8.5%) and fasting blood glucose level (from 209 to 154 mg/dl). Although the change in fasting blood glucose approached statistical significance, these measures of glucose homeostasis did not achieve significance. Cholesterol and triglycerides increased slightly, and C-peptide decreased slightly over 1 year. These changes were not statistically significant.
Although this is a small series, our data show that at 12 months after surgery, clinical improvement was obvious in all of our seven patients, but LDJB may not be effective at inducing remission of T2DM and the MS in certain patients undergoing this operation. This suggests that larger patient studies should be conducted, before concluding that surgery may offer clinical and biochemical resolution to a disease once treated only medically. Longer follow-up is required for better evaluation.
We thank Kell Julliard for his assistance with the statistical calculations.
- 3.Centers for Disease Control website. www.CDC.com
- 4.Harris MI (1995) Summary. In: National diabetes data group (ed) Diabetes in America. NIH publ. 95-1468, 2nd edn. Government Printing Office, Washington, DC, pp 1–14Google Scholar
- 5.International Diabetes Federation Task Force on Diabetes Health Economics (1997) Diabetes health economics: facts, figures, and forecasts. International Diabetes Federation, BrusselsGoogle Scholar
- 15.Cohen RV (2007) Duodenojejunal bypass for the treatment of type II diabestes mellitus in patients with BMI 22-34. Presented at the center for the surgical treatment of morbid obesity and metabolic disorders, Hospital Sao Camilo and Baros Surgical Associates, Sao Paulo, BrazilGoogle Scholar
- 19.ACCORD trial protocol. Accessed at www.ACCORD.org